The glutamate hypothesis: A pathogenic pathway from which pharmacological interventions have emerged

Pharmacopsychiatry

Volumn 47, Issue 4-5, 2014, Pages 121-130

  Veerman, S R T ^a   Schulte, P F J ^b   De Haan, L ^c  

^a Mental Health Care Organization North Holland North   (Netherlands)

^b Treatment Centre for Bipolar Disorders   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

clozapine; glutamate; glycine; NMDA receptor; schizophrenia

Indexed keywords

CLOZAPINE; GLUTAMATE RECEPTOR AGONIST; GLUTAMATE RECEPTOR ANTAGONIST; GLUTAMIC ACID; IONOTROPIC RECEPTOR AGONIST; MEMANTINE; METABOTROPIC RECEPTOR AGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; AMINO ACID RECEPTOR BLOCKING AGENT; AMINO ACID RECEPTOR STIMULATING AGENT; GLUTAMATE RECEPTOR;

ARTICLE; COGNITIVE DEFECT; HUMAN; HYPOTHESIS; NEGATIVE SYNDROME; NEUROTRANSMISSION; PATHOPHYSIOLOGY; POSITIVE SYNDROME; PRIORITY JOURNAL; SYNAPTIC TRANSMISSION; DRUG COMBINATION; DRUG DELIVERY SYSTEM; DRUG EFFECTS; METABOLISM; SCHIZOPHRENIA;

CLOZAPINE; DRUG DELIVERY SYSTEMS; DRUG THERAPY, COMBINATION; EXCITATORY AMINO ACID AGONISTS; EXCITATORY AMINO ACID ANTAGONISTS; GLUTAMIC ACID; HUMANS; MEMANTINE; RECEPTORS, GLUTAMATE; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA;

EID: 84904823964     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0034-1383657     Document Type: Article

References (73)

1. Buchanan R. W., Davis M., Goff D. et al. A Summary of the FDANIMH-MATRICS Workshop on Clinical Trial Design for Neurocognitive Drugs for Schizophrenia. Schizophr Bull: 2005; 31 5 19 (Pubitemid 41214353)
2. Heaton R. K., Gladsjo J. A., Palmer B. W. et al. Stability and course of neuropsychological deficits in schizophrenia. Arch Gen Psychiatry: 2001; 58 24 32 (Pubitemid 32057762)
3. Javitt D. C. glutamate involvement in schizophrenia: focus on N-methyl-D-aspartate receptors. Prim Psychiatry: 2006; 13 38 46 (Pubitemid 44571906)
4. Stone J. M., Morrison P. D., Pilowsky L. S. Review: glutamate and dopamine dysregulation in schizophrenia - a synthesis and selective review. J Psychopharmacol: 2007; 21 440 452 (Pubitemid 47077295)
5. Kontaxakis V. P., Ferentinos P. P., Havaki-Kontaxaki B. J. et al. Randomized controlled augmentation trials in clozapine-resistant schizophrenic patients: a critical review. Eur Psychiatry: 2005; 20 409 415 (Pubitemid 41318007)
6. Schulte R. Clozapin bei therapieresistenter Schizophrenie. Plasmaspiegel und Dauer eines ausreichenden Behandlungs-versuchs. Psychopharmakotherapie: 2003; 1 11
7. Loonen AJ M., Stahl S. M. Functional psychopharmacology is the way to go in pharmacotherapy for psychiatric disorders. Acta Psychiatr Scand: 2010; 122 435 437
8. Kornmeier J., Sosic-Vasic Z. Parallels between spacing effects during behavioural and cellular learning. Front Hum Neurosci: 2012; 6 203
9. Goff D. C., Coyle J. T. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry: 2001; 158 1367 1377 (Pubitemid 32847232)
10. Papanastasiou E., Stone J. M., Shergill S. When the drugs don't work: the potential of glutamatergic antipsychotics in schizophrenia. Br J Psychiatry: 2013; 202 91 93
11. Harrison P. J., Lyon L., Sartorius L. J. et al. The group II metabotropic glutamate receptor 3 (mGluR3, mGlu3, GRM3): expression, function and involvement in schizophrenia. J Psychopharmacol: 2008; 22 308 322 (Pubitemid 351847454)
12. Marino M. J., Conn P. J. Direct and indirect modulation of the N-methyl D-aspartate receptor. Curr Drug Targets CNS Neurol Disord: 2002; 1 1 16
13. Fell M. J., McKinzie D. L., Monn J. A. et al. Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia. Neuropharmacology: 2012; 62 1473 1483
14. Allen P., Luigjes J., Howes O. D. et al. Transition to psychosis associated with prefrontal and subcortical dysfunction in ultra high-risk individuals. Schizophr Bull: 2012; 38 1268 1276
15. Moghaddam B., Adams B., Verma A. et al. Activation of glutmatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci: 1997; 17 2921 2927 (Pubitemid 27155025)
16. Tiihonen J., Wahlbeck K. Glutamatergic drugs for schizophrenia. Cochrane Database of Systematic Reviews: 2006; Issue 2. Art. No.: CD003730
17. Takata A., Iwayama Y., Fukuo Y. et al. A population-specific uncommon variant in GRIN3A associated with schizophrenia. Biol Psychiatry: 2013; 73 532 539
18. Wandinger K. P., Saschenbrecker S., Soecker W. et al. Anti-NMDA-receptor encephalitis: A severe, multistage, treatable disorder presenting with psychosis. J Neuroimmunol: 2011; 231 86 91
19. Steiner J., Walter M., Glanz W. et al. Increased prevalence of diverse N-methyl-D-aspartate glutamate receptor antibodies in patients with an initial diagnosis of schizophrenia: specific relevance of IgG NR1a antibodies for distinction from N-methyl-D-aspartate glutamate receptor encephalitis. JAMA Psychiatry: 2013; 70 271 278
20. 1H-MRS studies. Schizophr Bull: 2011; 1 10
21. Homayoun H., Moghaddam B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci: 2007; 27 11496 11500 (Pubitemid 350006886)
22. Gordon J. A. Testing the glutamate hypothesis of schizophrenia. Nat Neurosci: 2010; 13 2 4
23. Jackson M., Homayoun H., Moghaddam B. NMDA receptor hypofunction produces concomitant firing rate potentiation and burst activity reduction in the prefrontal cortex. Proc Natl Acad Sic USA: 2004; 101 6391 6396
24. Singh S. P., Singh V. Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia. CNS drugs: 2011; 25 859 885
25. Goff D. C., Leahy L., Berman I. et al. A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. J Clin Psychopharmacol: 2001; 21 484 487 (Pubitemid 32937430)
26. Conn P. J., Lindsley C. W., Jones C. K. Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. Trends in Pharmacol Sci: 2009; 30 25 31
27. Fraley M. E. Positive allosteric modulators of the metabotropic glutamate receptor 2 for the treatment of schizophrenia. Expert Opin Ther Pat: 2009; 19 1259 1275
28. Patil S. T., Zhang L., Martenyi F. et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial. Nat Med: 2007; 13 1102 1107 (Pubitemid 47517511)
29. Kinon B. J., Zhang L., Millen B. A. et al. HBBI Study Group A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia. J Clin Psychopharmacol: 2011; 31 349 355
30. Kinon B., Millen B. A., Downing A. C. et al. LY, 2140023 monohydrate in the treatment of patients with schizophrenia: results of 2 clinical trials assessing efficacy in treating acutely ill and those with prominent negative symptoms. Schizophr Bull: 2013; 39 S338
31. Adams D. H., Kinon B. J., Baygani S. et al. A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia. BMC Psychiatry: 2013; 13 143
32. Adams D. H., Zhang L., Millen B. A. et al. Pomaglumetad methionil (LY2140023 monohydrate) and aripiprazole in patients with schizophrenia: a phase 3, multicenter, double-blind comparison. Schizophr Res Treatment: 2014; 1 11
33. Trabanco A. A., Cid J. M. mGluR2 positive allosteric modulators: a patent review (2009-present). Expert Opin Ther Pat: 2013; 23 629 647
34. Hopkins C. R. Is there a path forward for mGlu(2) positive allosteric modulators for the treatment of schizophrenia? ACS Chem Neurosci: 2013; 20 211 213
35. Javitt D. C. Twenty-five years of glutamate in schizophrenia: are we there yet? Schizophr Bull: 2012; 38 911 913
36. Emmett M. R., Mick S. J., Cler J. A. et al. Actions of D-cycloserine at the N-methyl-D-aspartate-associated glycine receptor site in vivo. Neuropharmacology: 1991; 30 1167 1171
37. Lane H. Y., Huang C. L., Wu P. L. et al. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. Biol Psychiatry: 2006; 60 645 649
38. Kane J., Honigfeld G., Singer J. et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry: 1988; 45 789 796
39. Naheed M., Geen B. Focus on clozapine. Curr Med Res Opin: 2001; 17 223 229 (Pubitemid 34003125)
40. Howes O. D., Egerton A., Allan V. et al. Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights form PET and SPECT imaging. Current Pharmaceutical Design: 2009; 15 2550 2559
41. Yeun E. Y., Zhong P., Yan Z. Homeostatic regulation of glutamatergic transmission by dopamine D4 receptors. Proc Natl Acad Sci USA: 2010; 107 22308 22313
42. Tanahashi S., Yamamura S., Nakagawa M. et al. Clozapine, but not haloperidol, enhances glial D-serine and L-glutamate release in rat frontal cortex and primary cultured astrocytes. Br J Pharmacol: 2012; 165 1543 1555
43. Veerman SR T., Schulte PF J., Begemann MJ H. et al. Clozapine Augmented with Glutamate Modulators in Refractory Schizophrenia: A Review and Meta-analysis. Pharmacopsychiatry: 2014; in press
44. Joshi I., Yang Y-M, Wang L-Y. Cellular/molecular coincident activation of metabotropic glutamate receptors and NMDA receptors (NMDARs) downregulates perisynaptic/extrasynaptic NMDARs and enhances high-fidelity neurotransmission at the developing calyx of the held synapse. J Neurosci: 2007; 27 9989 9999 (Pubitemid 47403997)
45. Tiihonen J., Hallikainen T., Ryynänen O. P. et al. Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial. Biol Psychiatry: 2003; 54 1241 1248 (Pubitemid 37464870)
46. Tiihonen J., Halonen P., Wahlbeck K. et al. Topiramate add-on in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. J Clin Psychiatry: 2005; 66 1012 1015 (Pubitemid 41191793)
47. Behdani F., Hebrani P., Rezaei Ardani A. et al. Effect of topiramate augmentation in chronic schizophrenia: a placebo-controlled trial. Arch Iran Med: 2011; 14 270 275
48. Tsouli S., Konitsiotis S. How should we treat a patient with early Parkinson's disease? Int J Clin Pract: 2010; 64 1210 1219
49. Ossola B., Schendzielorz N., Chen S. H. et al. Amantadine protects dopamine neurons by a dual action: reducing activation of microglia and inducing expression of GDNF in astroglia. Neuropharmacology: 2011; 61 574 582
50. de Lucena D., Fernandes B. S., Berk M. et al. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine. J Clin Psychiatry: 2009; 70 1416 1423
51. Kremer I., Vass A., Gorelik I. et al. Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia. Biol Psychiatry: 2004; 56 441 446 (Pubitemid 39195324)
52. Kishi T., Iwata N. NMDA receptor antagonists interventions in schizophrenia: Meta-analysis of randomized, placebo-controlled trials. J Psychiatr Res: 2013; 1 7
53. Angus S., Sugars J., Boltezar R. et al. A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia. J Clin Psychopharmacol: 1997; 17 88 91 (Pubitemid 27148302)
54. Silver H., Goodman C., Isakov V. et al. A double-blind, cross-over comparison of the effects of amantadine or placebo on visuomotor and cognitive function in medicated schizophrenia patients. Int Clin Psychopharmacol: 2005; 20 319 326 (Pubitemid 41475322)
55. Pappa S., Tsouli S., Apostolou G. et al. Effects if amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Clin Neuropharmacol: 2010; 33 271 275
56. Rezaei F., Mohammad-karimi M., Seddighi S. et al. Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol: 2013; 33 1 7
57. Lieberman J. A., Papadakis K., Csernansky J. et al. MEM-MD-29 Study Group A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia. Neuropsychopharmacology: 2009; 34 1322 1329
58. Lee J. G., Lee S. W., Lee B. J. et al. Adjunctive memantine therapy for cognitive impairment in chronic schizophrenia: a placebo-controlled pilot study. Psychiatry Investig: 2012; 9 166 173
59. Os van J., Kahn R. Remissiecriteria voor de diagnose schizofrenie. Tijdschr Psychiatr: 2007; 49 21 26 (Pubitemid 46150732)
60. Areosa S. A., Sherriff F., McShane R. Memantine for dementia. Cochrane Database Syst Rev: 2005; CD003154
61. Winblad B., Jones R. W., Wirth Y. et al. Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials. Dement Geriatr Cogn Disord: 2007; 24 20 27 (Pubitemid 46985287)
62. Levaux M. N., Potvin S., Sepehry A. A. et al. Computerized assessment of cognition in schizophrenia: Promises and pitfalls of CANTAB. Eur Psychiatry: 2007; 22 104 115 (Pubitemid 46274188)
63. Guy W. Clinical Global Impression Scale. In Guy W. ECDEU Assessment Manual for Psychopharmacology- Revised. Rockville MD US Dept. of Health, Education and Welfare, ADAMHA, MIMH Psychopharmacology Research Branch: 1976; 218 222
64. Kay S. R., Flszbein A., Opfer L. A. The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia. Schizophr Bull: 1987; 13 261 276 (Pubitemid 18039085)
65. Baron-Cohen S., Wheelwright S., Hill J. et al. The Reading the Mind in the Eyes Test revised version: a study with normal adults, and adults with Asperger syndrome or high-functioning autism. J Child Psychol Psychiatry: 2001; 42 241 251 (Pubitemid 32233124)
66. Wing J., Lelliott P., Chaplin R. H. Reliability and validity of HoNOS (multiple letters). Psychiatric Bull: 1999; 23 375 (Pubitemid 29265328)
67. Priebe S., Huxley P., Knight S. et al. Application and results of the Manchester Short Assessment of Quality of Life (MANSA). Int J Soc Psychiatry: 1999; 45 7 12 (Pubitemid 29158596)
68. Zdanys K., Tampi R. R. A systematic review of off-label uses of memantine for psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry: 2008; 32 1362 1374 (Pubitemid 352033662)
69. Muhonen L. H., Lönnqvist J., Juva K. et al. Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence. J Clin Psychiatry: 2008; 69 392 399 (Pubitemid 351549391)
70. Stewart S. E., Jenike E. A., Hezel D. M. et al. A single-blinded case-control study of memantine in severe obsessive-compulsive disorder. J Clin Psychopharmacol: 2010; 30 34 39
71. Addington D., Addington J., Schissel B. A depression rating scale for schizophrenics. Schizophr Res: 1990; 3 247 251 (Pubitemid 20228720)
72. Goodman W. K., Price L. H., Rasmussen S. A. et al. The Yale-Brown Obsessive Compulsive Scale. Arch Gen Psychiatry: 1989; 46 1012 1016
73. Day J. C., Wood G., Dewey M. et al. A self-rating scale for measuring neuroleptic side-effects. Validation in a group of schizophrenic patients. Br J Psychiatry: 1995; 166 650 653